Early-stage breast cancer patients in the U.S. may soon be able to access another treatment regime based on the result of a Nov. 7 FDA advisory committee for the Prosense cryoablation system by Icecure Medical Ltd. The advisory committee voted 9-5 that the benefits of Prosense outweigh the risks, although the FDA has yet to decide on the application.
Scientists at Meta Pharmaceutical (HK) Ltd. and Shenzhen Moyuan Pharmaceuticals Co. Ltd. have disclosed lactate dehydrogenase A (LDHA) inhibitors reported to be useful for the treatment of cancer, allergy, among others.
Nonselective poly(ADP-ribose) polymerase (PARP) inhibitors have shown antitumoral activity, but they are tied to hematotoxicity, most probably due to PARP2 inhibition. Instead, selective PARP inhibitors retain antitumoral activity without risking PARP2-related toxicity.
Researchers from Zymeworks Inc. recently reported preclinical data for ZW-220, an antibody-drug conjugate (ADC) consisting of humanized IgG1 monoclonal antibody targeting sodium-dependent phosphate transport protein 2B (SLC34A2, NaPi2b) conjugated to a topoisomerase I inhibitor, being developed for the treatment of cancer.
KAT6 is a histone lysine acetyl transferase involved in the epigenetic regulation of oncogenes and it is often dysregulated in cancer, including breast cancer. Inhibiting KAT6 blocks the transcription of genes such as ESR1 and CCND1 and the use of KAT6 inhibitors together with endocrine therapy and CDK4/6 inhibitor therapy may enhance the effectiveness in cancer.
Antibody-drug conjugates (ADCs) combine monoclonal antibody-targeting capabilities with the cytotoxic effect of conjugated drug payloads. However, there is a need for enhanced strategies to overcome restricted therapeutic window or unacceptable off-target effects.
The University of Texas MD Anderson Cancer Center has launched its Institute for Cell Therapy Discovery & Innovation, which seeks to build upon MD Anderson clinical and research expertise to advance impactful cell therapies.
Evolveimmune Therapeutics Inc. has unveiled EVOLVE-205, a new 2:1 T-cell engager targeting CD20 with integrated affinity-tuned CD3 and CD2 agonists to promote anti-B-cell immunity.
RSS
